• Small Molecules
      • Discovery
        Development
        Manufacturing
    • Biologics
      • Discovery
        Development & Manufacturing
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery

      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

        Know More
        Know More
    • Industries
    • Emerging Biopharma

      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

        Know More
        Know More
    • Dedicated Centers

      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

        Know More
        Know More
    • Center for Advanced Protein Studies (CAPS)

      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

        Know More
        Know More
    • Investors
      Corporate Governance
  • Careers

Videos

Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.

Resource Types

CFO Sibaji Biswas' year-end reflections and outlook for FY24

Watch this video where our CFO, Sibaji Biswas, shares his perspective on a trend-breaking year with revenue growth of 23% year-on-year. Syngene delivered the highest absolute year-on-year increase in revenue and EBITDA compared to the last five years. While the research business and Dedicated Centers delivered a strong performance, Development and Manufacturing services grew by 28% year-on-year. To read the full press release, click here.

MD & CEO Jonathan Hunt’s year-end reflections and outlook for FY24

Watch this video where our MD and CEO, Jonathan Hunt, shares his perspective on the financial year gone by and the outlook for FY24. Syngene’s sustained positive performance in the fourth quarter delivered strong full-year results. Revenue from operations in Q4 grew by 31%, while full-year revenue from operations in FY 23 grew by 23%. To read the press release, click here.

MD and CEO, Jonathan Hunt on Syngene's annual performance and outlook for FY23

Syngene reported a 19% growth in revenue from operations for the entire year of FY22. Watch this video as our CEO and MD, Jonathan Hunt, speaks about Syngene’s performance, the outlook for FY 23, Syngene’s contribution in the fight against the pandemic, focus areas for the coming year, and more.

Syngene International Corporate video

Catch a glimpse of our ~ 2 Mn sq. ft. world-class R&D and manufacturing facility to understand how we put Science to Work at Syngene. We are an innovation-led, contract research, development & manufacturing organization offering integrated scientific services from early discovery to commercial supply.

Syngene’s Early-stage Chemistry Process Research Lab for drug discovery

Watch this video on our Early-stage Chemistry Process Research Lab for drug discovery that supports pre-clinical studies, medicinal chemistry, and integrated project requirements (from mg to kg scale).

Syngene FY22 Highlights

Syngene reported a 19% growth in revenue from operations for the full year (FY22). Watch this video to learn more about our performance, business highlights, awards & recognitions, and more.

Syngene’s Sterile Fill-Finish facility for Clinical Supplies – Biologics & Small Molecules

In this video, Syngene scientist Saurabh Sahu takes you through the capabilities and features of our integrated Sterile Fill-Finish facility for clinical supplies of Biologics and Small Molecules, as well as, products that are sensitive to light, heat and oxygen.

Syngene FY21 Highlights

Syngene reported 12% growth in revenue from operations for the full year of FY21. Watch this video, to know more about our company performance, business highlights, COVID-19 updates and more.

Syngene COVID-19 Testing Center using qRT-PCR

Want to know, how Syngene conducts RT-PCR testing at its COVID-19 Testing laboratory? Approved by Indian Council of Medical Research (ICMR), this lab has tested more than 100000+ samples so far.

Syngene Large Molecule Bioanalytical Laboratory

Explore Syngene’s Large Molecule Bioanalytical Laboratory, which is India’s premier GLP- certified and GCLP-compliant lab. It specializes in immunogenicity and pharmacokinetic (PK) analysis of biologics and biosimilars.

Syngene Discovery Chemistry facility, Hyderabad

Explore our new 52,000 sq.ft., state-of-the-art R&D center in Genome valley, Hyderabad. Focused on Discovery Chemistry services, we are excited to be expanding our facilities to assist more clients accelerate their research programs.

Syngene API manufacturing facility, Mangaluru

Our GMP-certified, API manufacturing facility in Mangaluru is a state-of-the-art, multi-product, multi-client, contract facility. Spread across 46 acres, it is designed to support all large-scale API and advanced intermediate manufacturing requirements of our clients.

Sign-up for our newsletter

© 2023. Syngene International Limited

Twitter Linkedin-in Youtube Facebook-f

Quick Links

Business

Get In Touch

Other Links

Twitter Linkedin-in Youtube Facebook-f

© 2023. Syngene International Limited

Download PDF
Download PDF

Your browser does not support this function.

To download, Please share your details

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements.

To find out more, read our Privacy Policy and Cookies Policy.

Close
Close

To view or email, Please share your details view

To download, Please share your details